Veradermics (MANE) Stock Price, Quote, News & History | Benzinga

Veradermics Inc (MANE) Stock Price, Quote, News & History

MANENYSE

Trade with Public

Trade with Public

$112.71

1.711.54%

At close: Aug 14, 5:00 PM EST

$112.00

-0.71-0.63%

After Hours: Aug 14, 7:17 PM EST

Earnings: Q2 2026 Earnings were released on Tue Aug 11th, before the market open

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$110.28

Close

$112.71

Volume / Avg.

523.47K / 693.16K

Day Range

$109.84 - $113.52

52 Wk Range

32.00 - 131.24

Market Cap

$4.68B

P/E Ratio

-

Dividend Yield

-

Exchange

NYSE

RSI

52

Short Interest

17.72%

Days to Cover

6.92

Recent Veradermics, Incorporated News

Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months

Veradermics reported positive phase 2 data for VDPHL01, showing hair growth and favorable safety in women with pattern hair loss.

Vandana Singh

PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday

US stocks close higher, Dow Jones up 100 points, PayPal shares rise on $53 billion acquisition proposal, other big gains from Aehr Test, Electrovaya, Robo.ai, Falcon's Beyond, Veradermics, Lucid Group, Kopin, MINISO, Mesoblast, Nexstar, Lionsgate, Karman.

Avi Kapoor

This Oppenheimer Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Wall Street analysts changed outlook on top names: ODTX, MOBI, MANE. See analyst ratings page for all changes. MOBI target prices: $16, $19, $31

Avi Kapoor

Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings

U.S. stocks trade lower on Monday, with Dow falling 0.1%. Verizon beats Q1 earnings, raises FY26 guidance. European shares mixed, Asian markets close mixed.

Avi Kapoor

Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains

Veradermics reports Phase 2/3 data for VDPHL01, showing significant hair growth and a safety profile, with shares rising on Monday.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-78.30M

Investing Cash Flow (TTM)

-473.36M

Financing Cash Flow (TTM)

862.40M

Free Cash Flow (TTM)

-78.33M

Capital Expenditure (TTM)

-26.00K

Net Change in Cash (TTM)

310.74M

Analyst Trends and Forecast

4

Mar

1

Apr

1

May

2

Jun

4

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$3.89B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

5.70

Earnings Yield % (TTM)

-2.25%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$19.47

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$319.33M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$110.28

Close

$112.71

Volume / Avg.

523.47K / 693.16K

Day Range

$109.84 - $113.52

52 Wk Range

32.00 - 131.24

Market Cap

$4.68B

P/E Ratio

-

Dividend Yield

-

Exchange

NYSE

RSI

52

Short Interest

17.72%

Days to Cover

6.92

About

Sector

Health Care

Industry

Pharmaceuticals

Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resourc...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Veradermics (MANE) stock?

A

You can purchase shares of Veradermics (NYSE:MANE) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Veradermics (MANE) competitors?

A

Other companies in Veradermics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Veradermics (MANE) stock?

A

Veradermics has a consensus price target of $150.17.

Q

What is the current price for Veradermics (MANE)?

A

The stock price for Veradermics (NYSE: MANE) is $112 last updated August 14, 2026 at 7:17 PM EDT.

Q

Does Veradermics (MANE) pay a dividend?

A

There are no upcoming dividends for Veradermics.

Q

When is Veradermics (NYSE:MANE) reporting earnings?

A

Veradermics does not have any upcoming earnings scheduled.

Q

Is Veradermics (MANE) going to split?

A

There is no upcoming split for Veradermics.

Q

What sector and industry does Veradermics (MANE) operate in?

A

Veradermics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NYSE.